| Literature DB >> 31706301 |
Misako Konishi1, Sota Kobayashi2, Taeko Tokunaga3, Yuzumi Chiba4, Toshiyuki Tsutsui5, Shozo Arai6, Ken-Ichiro Kameyama7, Takehisa Yamamoto8.
Abstract
BACKGROUND: Enzootic bovine leukosis (EBL) is a disease of cattle caused by bovine leukemia virus (BLV). More than 60% of BLV-infected cattle remain subclinical and are thus referred to as aleukemic (AL) cattle. Approximately 30% of infected cattle show a relatively stable increase in the number of B lymphocytes; these cattle are termed persistent lymphocytosis (PL) cattle. A small percentage of infected cattle develop BLV-induced B cell lymphoma (EBL) and are called EBL cattle. Due to the increase in the number of BLV-infected cattle, the number of EBL cattle has featured a corresponding increase over recent years in Japan. Several diagnostic criteria for EBL (e.g., enlarged superficial lymph nodes, protrusion of the eye, increased peripheral blood lymphocyte, etc.) are used for on-farm diagnosis and antemortem tests at slaughterhouses. Since the slaughter of EBL cattle for human consumption is not allowed, on-farm detection of EBL cattle is important for reducing the economic loss incurred by farms. Therefore, establishing new diagnostic markers to improve the efficiency and accuracy of the antemortem detection of EBL cattle is a critical, unmet need. To simultaneously evaluate the utility of candidate markers, this study measured the values of each marker using the blood samples of 687 cattle with various clinical statuses of BLV infection (EBL, PL, AL and non-infected cattle).Entities:
Keywords: Biomarker; Cattle; Enzootic bovine leukosis; Lactate dehydrogenase; Thymidine kinase
Mesh:
Substances:
Year: 2019 PMID: 31706301 PMCID: PMC6842470 DOI: 10.1186/s12917-019-2158-4
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Test results for each marker and the results of ROC analysis
| Marker*1 | Unit | EBL cattle*2 | Non-EBL cattle*3, *4 | Thresholds*5 | AUC (95%CI)*6 | Se (%)*7 | Sp (%)*8 | ||
|---|---|---|---|---|---|---|---|---|---|
| Mean | Median (95 percentile) | Mean | Median (95 percentile) | ||||||
| TK | Du/L | 2805.6 | 2321 (97.2–10,031.0) | 23.73 | 12.5 (−70.475–162.8) | 99.7 | 0.98 (0.96–1.00) | 97.1 | 97.0 |
| LDH2 | IU/L | 1084.1 | 936.9 (169.5–2602.3) | 397.8 | 288 (146.2–1244.4) | 460.6 | 0.87 (0.83–0.91) | 82.8 | 81.7 |
| Total LDH | IU/L | 3743 | 3038 (812.3–10,010.1) | 1695.1 | 1002 (544.0–7428.8) | 1389 | 0.85 (0.81–0.89) | 87.5 | 75.8 |
| LDH3 | IU/L | 693.9 | 634.4 (86.0–1735.7) | 267.2 | 168.2 (75.2–1048.8) | 283.7 | 0.85 (0.80–0.89) | 82.2 | 79.7 |
| TNFR II/I | – | 0.93 | 0.68 (0.06–4.15) | 0.26 | 0.17 (0.09–0.80) | 0.3 | 0.85 (0.79–0.90) | 81.7 | 81.8 |
| LDH1 | IU/L | 1100.3 | 920.7 (335.6–2708.6) | 602.7 | 438.5 (270.2–1843.5) | 564.5 | 0.83 (0.79–0.87) | 82.2 | 75.1 |
| LDH4 | IU/L | 485.5 | 168.6 (24.9–1330.9) | 143.6 | 63.9 (20.5–829.0) | 91.6 | 0.77 (0.72–0.82) | 79.3 | 74.6 |
| No. of lymphocytes | 102/ul | 316.8 | 108 (16.7–2112.0) | 46.4 | 34 (13.0–138.3) | 75.5 | 0.76 (0.70–0.81) | 61.3 | 73.2 |
| PVL | copies/10 ng DNA | 3289.8 | 1969.3 (28.3–16,224.0) | 1536.6 | 779.9 (0.0–5729.7) | 3433.1 | 0.69 (0.63–0.75) | 51.9 | 72.4 |
| LDH5 | IU/L | 289.94 | 66.45 (9.7–1881.9) | 285.76 | 41.5 (10.5–2574.0) | 54.5 | 0.6 (0.54–0.66) | 60.9 | 62.9 |
*1 TK: thymidine kinase; LDH: lactate dehydrogenase; TNFR: tumor necrosis factor receptor; PVL: proviral load. *2 EBL cattle: cattle affected with BLV-induced lymphoma; 95 percentile: lower and upper limit of 95 percemtile *3 Non-EBL cattle: cattle without BLV-induced lymphoma (including non-infected cattle) *4 Data from non-infected cattle were not included for statistical analysis of PVL *5 Thresholds were calculated by using receiver operating characteristic (ROC) analysis *6 AUC: Area under the curve at the threshold *7 Se: sensitivity for the detection of EBL cattle at the threshold *8 Sp: specificity for the detection of EBL cattle at the threshold
Fig. 1Comparison of distribution of measured values by clinical state 1 Distribution of measured values of a number of lymphocytes, b proviral load in peripheral blood, c TNFR II/I, and d TK. Each marker was compared by clinical status as follows. Non-infected: cattle not infected with bovine leukemia virus (BLV); AL: aleukemic cattle; PL: persistent lymphocytosis cattle; EBL: cattle affected with BLV-induced lymphoma. Measured values were transformed to common logarithms (log10). * indicates significant difference between EBL cattle and non-EBL cattle according to Mann-Whitney test (p < 0.05). Same letters indicate significant differences between BLV infection statuses as determined by the Kruskal-Wallis test and subsequent Bonferroni’s multiple comparisons test (p < 0.05)
Fig. 2Comparison of distribution of measured values by clinical state 2 Distribution of measured values of a tLDH, b LDH1, c LDH2, d LDH3, e LDH4, and f LDH5. Each marker was compared by clinical status as follows. Non-infected: cattle not infected with bovine leukemia virus (BLV); AL: aleukemic cattle; PL: persistent lymphocytosis cattle; EBL: cattle affected with BLV-induced lymphoma. Measured values were transformed to common logarithms (log10). * indicates significant difference between EBL cattle and non-EBL cattle according to Mann-Whitney test (p < 0.05). Same letters indicate significant differences between BLV infection statuses as determined with the Kruskal-Wallis test and subsequent Bonferroni’s multiple comparisons test (p < 0.05)
Details of cattle used in this study
| Status*1 | Total | Age (years old) | Sex | Breed | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2> | 3–5 | 6 | UK*2 | Female | Male/ Castrated | UK | Dairy | Beef | UK*2 | |||
| EBL | 281 | 48 | 97 | 128 | 8 | 253 | 23 | 5 | 166 | 113 | 2 | |
| Non_EBL | Non-infected | 208 | 109 | 46 | 47 | 6 | 174 | 28 | 6 | 120 | 85 | 3 |
| AL | 147 | 33 | 58 | 56 | 0 | 143 | 4 | 0 | 92 | 55 | 0 | |
| PL | 51 | 3 | 23 | 25 | 0 | 51 | 0 | 0 | 49 | 2 | 0 | |
| Total | 687 | 193 | 224 | 256 | 14 | 621 | 55 | 11 | 427 | 255 | 5 | |
*1 EBL: cattle with BLV-induced lymphoma; non-infected: cattle without BLV infection; AL: aleukemic cattle; PL: persistent lymphocytosis cattle; *2 UK: unknown
Number of tested cattle for each marker
| Number of cattle | Status* | |||
|---|---|---|---|---|
| EBL | Non-infected | AL | PL | |
| Total | 281 | 208 | 147 | 51 |
| Number of lymphocytes | 150 | 160 | 147 | 51 |
| PVL | 210 | 149 | 94 | 40 |
| tLDH | 184 | 178 | 147 | 51 |
| LDH isozyme | 174 | 174 | 146 | 51 |
| TK | 138 | 65 | 44 | 22 |
| TNFR II/I | 153 | 76 | 47 | 30 |
*EBL: cattle with BLV-induced lymphoma; non-infected: cattle without BLV infection; AL: aleukemic cattle; PL: persistent lymphocytosis cattle
Primers used for RT-PCR
| Gene | Primer sequence (forward and reverse)* | Reference No. |
|---|---|---|
| Bovine TNFRI | 5′-GGATCCCTAATACGACTCACTATAGGGAGACGCCTCTGTCGTCTTAGCAT-3’ | [ |
| 5′-AAGTTCCAGT CCTGTCTCCA-3’ | ||
| Bovine TNFRII | 5′-CTAATACGACTCACTATAGGGAGACTCGACCAGCAGCACGGACA-3’ | |
| 5′-GCGTCTGTGTCCCTCGTGGA-3’ | ||
| Bovine β-actin | 5′-CTAATACGACTCACTATAGGGAGACGCACCACTGGCATTGTCAT-3’ | [ |
| 5′-TCCAAGGCGACGTAGCAGAG-3’ |
*T7 promoter sequence and extra nucleotides were added at 5’end of each forward primer